NASDAQ Composite ended the session with Arena Pharmaceuticals jumping 2.13% to $66.76 on Tuesday while nASDAQ Composite slid 0.92% to $13,786.27.
Arena Pharmaceuticals today’s close was $66.76, 35.10% below its 52-week high of $90.19.
Arena Pharmaceuticals’s Sales
Arena Pharmaceuticals’s sales growth is 117.6% for the current quarter and a decline by 61.2% for the next. The company’s growth estimates for the present quarter and the next is a negative 6% and a negative 34.2%, respectively.
Arena Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth declined by 98.8%, now sitting on 319k for the twelve trailing months.
Arena Pharmaceuticals’s last day, last week, and last month’s current volatility was 0.81%, 1.78%, and 1.86%, respectively.
Arena Pharmaceuticals‘s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.17% (day), 3.87% (last week), and 4.11% (last month), respectively.
Arena Pharmaceuticals’s Stock Yearly Top and Bottom Value
Arena Pharmaceuticals’s stock is valued at $66.76 at 17:04 EST, way under its 52-week high of $90.19 and way higher than its 52-week low of $44.79.
Arena Pharmaceuticals’s Moving Average
Arena Pharmaceuticals’s value is way under its 50-day moving average of $75.23 and way below its 200-day moving average of $75.71.
More news about Arena Pharmaceuticals.